



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 May 2010
EMA/321004/2010
Committee for medicinal products for human use (CHMP)

Summary of opinion¹ (post authorisation)

Docetaxel Winthrop

docetaxel

On 20 May 2010 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Docetaxel Winthrop. The marketing authorisation holder for this medicinal product is Aventis Pharma S.A.. They may request a re-examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted *a new indication* as follows:

"DOCETAXEL WINTHROP in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

- operable node-negative breast cancer

For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1)."

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for Docetaxel Winthrop will be as follows²:

Breast cancer

DOCETAXEL WINTHROP in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

¹ Summaries of positive opinion are published without prejudice to the commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

² The text in bold represents the new or the amended indication.



- operable node-positive breast cancer
- **operable node-negative breast cancer**

For patients with operable nodenegative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1).

DOCETAXEL WINTHROP in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

DOCETAXEL WINTHROP monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

DOCETAXEL WINTHROP in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.

DOCETAXEL WINTHROP in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

Non-small cell lung cancer

DOCETAXEL WINTHROP is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.

DOCETAXEL WINTHROP in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.

Prostate cancer

DOCETAXEL WINTHROP in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Gastric adenocarcinoma

DOCETAXEL WINTHROP in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

Head and neck cancer

DOCETAXEL WINTHROP in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.